MannKind (MNKD) PT, Estimates Cut at Jefferies; 'Buy' Maintained

Jefferies analyst Shaunak Deepak lowered estimates and his price target on MannKind (NASDAQ: MNKD) to $9.00 (from $10.00) but is maintaining a Buy rating.

Deepak commented, "Despite early IMS scripts, physician feedback has made us more confident in the long-term sales potential of Afrezza. While we are maintaining our peak estimates, we are now assuming the Afrezza trajectory will take ten years, rather than six. As a result of this more gradual sales ramp, we are lowering lowering our PT from $10 to $9."

The firm cut FY 2015 EPS from $0.41 to ($0.42).

For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.

Shares of MannKind closed at $5.22 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
• Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns
• BofA Securities Upgrades Moderna (MRNA) to Neutral